Arcellx stock rating cut to Hold by TD Cowen on Gilead deal
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices soar as Middle East conflict spurs safe haven demand Oil prices surge after U.S.-Israel strikes on Iran; crude around $80/bbl likely Dollar surges on Middle East conflict; euro, sterling retreat Futures drop, oil spikes amid widening Mideast conflict - what’s moving markets FLASH SALE (South Africa Philippines Nigeria) FLASH SALE Arcellx stock rating cut to Hold by TD Cowen on Gilead deal By Investing.com Analyst Ratings Published 03/02/2026, 06:17 AM Arcellx stock rating cut to Hold by TD Cowen on Gilead deal 0 GILD 3.60% ACLX -0.08% Investing.com - TD Cowen downgraded Arcellx Inc. (NASDAQ:ACLX) to Hold from Buy following the Gilead acquisition offer. Analyst Tyler Van Buren said the firm views the Gilead acquisition offer as fair for both parties as it appropriately prices in anito-cel’s multi-billion dollar potential. The stock is trading at $113.79, near its 52-week high of $114.26, with a remarkable 74.5% year-to-date return. According to InvestingPro analysis, the company appears overvalued relative to its Fair Value estimate, which aligns with the acquisition timing. The analyst said the timing ahead of launch is rational. TD Cowen does not expect competing offers for Arcellx . InvestingPro Tips highlight the stock’s strong momentum with a 63% return over the last six months. For deeper insights, investors can access comprehensive Pro Research Reports covering ACLX and 1,400+ other US equities. The transaction is expected to close in the second quarter with no major events anticipated in the interim. TD Cowen downgraded the stock to Hold as its model matches the acquisition price. In other recent news, Gilead Sciences has announced its acquisition of Arcellx for approximately $7.8 billion, which includes a payment of $115 per share and a contingent value right of $5 per share. This acquisition has led several analyst firms to downgrade their ratings for Arcellx. Guggenheim downgraded Arcell...
Read full article at source